Signaling Pathway of GP88 (Progranulin) in Breast Cancer Cells: Upregulation and Phosphorylation of c-myc by GP88/Progranulin in Her2-Overexpressing Breast Cancer Cells
Author(s) -
Wes E. Kim,
Binbin Yue,
Ginette Serrero
Publication year - 2015
Publication title -
breast cancer basic and clinical research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.741
H-Index - 23
ISSN - 1178-2234
DOI - 10.4137/bcbcr.s29371
Subject(s) - phosphorylation , downregulation and upregulation , cancer research , autocrine signalling , breast cancer , mapk/erk pathway , signal transduction , proto oncogene tyrosine protein kinase src , kinase , tyrosine phosphorylation , cancer , chemistry , medicine , biology , receptor , microbiology and biotechnology , biochemistry , gene
Her2 is a receptor tyrosine kinase overexpressed in 25% of breast tumors. We have shown that the 88 kDa autocrine growth and survival factor GP88 (progranulin) stimulated Her2 phosphorylation and proliferation and conferred Herceptin resistance in Her2-overexpressing cells. Herein, we report that GP88 stimulates c-myc phosphorylation and upregulates c-myc levels in Her2-overexpressing cells. c-myc phosphorylation and upregulation by GP88 were not observed in non-Her2-overexpressing breast cancer cells. c-myc activation was inhibited upon treatment with ERK, PI3 kinase, and c-src pathway inhibitors, U0126, LY294002, and PP2. GP88 also stimulated c-src phosphorylation, a known upstream regulator of c-myc. Thus, we describe here a signaling pathway for GP88 in Her2-overexpressing cells, with GP88 stimulating Src phosphorylation, followed by phosphorylation and upregulation of c-myc. These data would suggest that targeting GP88 could provide a novel treatment approach in breast cancer.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom